An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.
Hyperfine, Inc. (Nasdaq: HYPR) annuncerà i risultati finanziari del primo trimestre del 2024 il 13 maggio 2024. L'azienda, nota per il suo sistema di imaging cerebrale MR portatile approvato dalla FDA, il sistema Swoop®, terrà una conferenza telefonica nello stesso giorno. L'evento sarà accessibile tramite la pagina degli investitori sul sito web di Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) anunciará sus resultados financieros del primer trimestre de 2024 el 13 de mayo de 2024. La compañía, conocida por su sistema de imágenes cerebrales por resonancia magnética portátil aprobado por la FDA, el sistema Swoop®, organizará una llamada de conferencia el mismo día. El evento se podrá seguir a través de la página de inversores en el sitio web de Hyperfine, Inc.
Hyperfine, Inc.(나스닥: HYPR)은 2024년 5월 13일에 2024년 제1분기 재무 결과를 발표할 예정입니다. FDA 승인을 받은 휴대용 MR 뇌 이미징 시스템인 Swoop® 시스템으로 유명한 이 회사는 같은 날 컨퍼런스 콜을 주최할 것입니다. 이 행사는 Hyperfine, Inc.의 웹사이트 투자자 페이지에서 접근할 수 있습니다.
Hyperfine, Inc. (Nasdaq: HYPR) annoncera ses résultats financiers pour le premier trimestre 2024 le 13 mai 2024. L'entreprise, connue pour son système d'imagerie cérébrale MR portable approuvé par la FDA, le système Swoop®, organisera une conférence téléphonique le même jour. L'événement sera accessible via la page des investisseurs du site Web de Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) wird am 13. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen, bekannt für sein von der FDA zugelassenes tragbares MR-Gehirnbildgebungssystem, das Swoop®-System, wird am selben Tag eine Telefonkonferenz veranstalten. Die Veranstaltung ist über die Investorenseite der Webseite von Hyperfine, Inc. zugänglich.
Positive
None.
Negative
None.
GUILFORD, Conn.--(BUSINESS WIRE)--
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
When will Hyperfine, Inc. report its first quarter 2024 financial results?
Hyperfine, Inc. will announce its first quarter 2024 financial results on May 13, 2024.
What is the stock symbol for Hyperfine, Inc.?
The stock symbol for Hyperfine, Inc. is HYPR.
What is the Swoop® system?
The Swoop® system is the first FDA-cleared portable MR brain imaging system developed by Hyperfine, Inc.
Where can participants access the live audio webcast of the presentation?
Participants can access the live audio webcast and presentation archive through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/.
hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of
